A newly approved rectal cancer drug could help eligible patients avoid chemo, radiation and surgery
AnaptysBio (ANAB) announced FDA approval for GSK's Jemperli (dostarlimab) to treat locally advanced rectal cancer, based on AZUR-1 trial data. The drug showed significant clinical responses, potentially avoiding chemo, radiation, and surgery. GSK will present full data at ESMO Congress 2026. ANAB manages financial collaborations for Jemperli.
How this was made
The 30-second read
Why it matters
The approval could drive significant royalty revenue for AnaptysBio and expand GSK's oncology pipeline, potentially boosting both stocks.
Market read
Regulatory approval is a primary catalyst that can move both GSK and ANAB stocks sharply.
What to watch
Reimbursement negotiations and competition from other PD‑1 blockers may limit upside.
Background
The FDA granted accelerated approval for Jemperli (dostarlimab) as a monotherapy for locally advanced rectal cancer, marking the first immunotherapy for this indication.
Ticker impact
FDA approval of Jemperli for MSI‑H/dMMR rectal cancer provides a new indication for GSK's immunotherapy.
upward pressure as investors price in future sales from the new indication
First FDA approval for this indication; GSK will capture market share from existing chemo/radiation regimens.
AnaptysBio manages the financial collaborations for Jemperli and benefits from royalty streams tied to the new FDA indication.
upward pressure as the market values higher future royalty cash flows
ANAB's business model is directly linked to Jemperli sales; new indication increases royalty base.
Market effects
Strengthens the oncology/immune‑oncology sector and may pressure competitors without similar approvals.
Positive for US and European biotech stocks focused on MSI‑H/dMMR therapies.
Adds to global pipeline momentum for PD‑1 inhibitors.
Counterpoint
If the drug fails to achieve commercial uptake, the hype could reverse quickly.
Key entities
- CompanyGSK
Global pharmaceutical company developing and commercializing Jemperli.
- CompanyAnaptysBio, Inc.
Biotech firm managing royalty collaborations for Jemperli.
